STAT3 and endometriosis: Since the IL-6/STAT3 axis is highly activated in endometriotic tissues compared with normal endometrium, JAK/STAT3 signaling inhibitors, such as curcumol and tofacitinib, effectively suppress endometriosis progression in rat and mouse endometriosis models, indicating STAT3 as a possible target for endometriosis treatment [86,87].